1Global initiative for chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (revised2013). [EB/OL]. [2012- 12-01 ]. http://www, goldcopd, org/uploads/users/files/GOLD_ Report_2013_Feb20. pdf.
3Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med, 2007, 176:753-760.
4Lindenauer PK, Pekow P, Gao S, et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 2006, 144: 894-903.
5Becker KL, Nylen ES, White JC, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis : a journey from calcitonin back to its precursors. J Clin Endocrinol Metab, 2004, 89:1512- 1525.
6Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon- alpha for differentiation of bacterial vs. viral infections. Pediatr Infect Dis J, 1999, 18:875-881.
7Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med, 1998, 24: 680-684.
8Albfich WC, Dusemund F, Bucher B, et al. Effectiveness and safety of procalcitonin-guided antibiotic therapy in lower respiratory tract infections in " real life ": an international, muhicenter poststudy survey (ProREAL). Arch Intern Med, 2012,172 : 715- 722.
9Falsey AR, Becker KL, Swinburne AJ, et al. Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis. 2012.7: 127-135.
10Schuetz P, Christ-Crain M, Thomann R, et al. Effect of Procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA, 2009,302:1059-1066.
5Marshall JC,Cook DA, Christon NV,et al.Muhiple organ dysfunction score:a reliable descriptor of a complex clinical outcome [J]. Lancet Infect Dis,2004,4 ( 7 ) :620-630.
6Meisner M,Tschaikowsky K,Hutzler A.Postoper at iveplasma concentrations of procalcitonin after different types of surgery [J].Intensive Care Med, 1998,24 ( 3 ) :680-684.
7Bossink AW,Groeneveld AB,Thijs LG.Prediction of microbial Infection and mortality in medical patients with fever.plasma procalcitonin, neutrophili elastase-alphal-antitrypsin, and lactofer in compared with clinical variable [J].Clin Infect Dis, 1999,29 (9):398- 407.
8Wanner GA,Keel M,Steckholzer U,et al,Relationship between procalcitonin plasma levels and severity of injury,sepsis,organ failure, and mortality in injured patien[J]. Care Med,2000,28 ( 11 ):950-957.
9Zeni F,Freeman BD,Natanson C,et al.Antiinflamatory therapies to treat sepsis and septic shock.Crit Care Med,1997,25:1095-1100.
10Luna CM,Blanzaco D,Niederman MS,et al.Resolution of ventilator-associated pneumonia:prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome.Crit Care Med,2003,31:676-682.
